Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 401245, 9 pages
http://dx.doi.org/10.1155/2014/401245
Research Article

Tissue Biomarkers in Prognostication of Serous Ovarian Cancer following Neoadjuvant Chemotherapy

1Department of Pathology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
2Department of Medical Oncology, Dr. B.R. Ambedkar Institute-Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
3Department of Gynecology and Obstetrics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
4Department of Biostatistics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India

Received 28 February 2014; Accepted 31 March 2014; Published 17 April 2014

Academic Editor: Kaei Nasu

Copyright © 2014 Binny Khandakar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Uma Devi, “Current status of gynecological cancer care in India,” Journal of Gynecologic Oncology, vol. 20, no. 2, pp. 77–80, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun, “Cancer statistics, 2009,” CA Cancer Journal for Clinicians, vol. 59, no. 4, pp. 225–249, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Kaku, S. Ogawa, Y. Kawano et al., “Histological classification of ovarian cancer,” Medical Electron Microscopy, vol. 36, no. 1, pp. 9–17, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. W.-Y. Chan, K.-K. Cheung, J. O. Schorge et al., “Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers,” American Journal of Pathology, vol. 156, no. 2, pp. 409–417, 2000. View at Google Scholar · View at Scopus
  6. V. W. Chen, B. Ruiz, J. L. Killeen, T. R. Coté, X. C. Wu, and C. N. Correa, “Pathology and classification of ovarian tumors,” Cancer, vol. 97, no. 10, supplement, pp. 2631–2642, 2003. View at Google Scholar
  7. H. W. Nijman, A. Lambeck, S. H. van der Burg, A. G. J. van der Zee, and T. Daemen, “Immunologic aspect of ovarian cancer and p53 as tumor antigen,” Journal of Translational Medicine, vol. 3, article 34, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Sassen, B. Schmalfeldt, N. Avril et al., “Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer,” Human Pathology, vol. 38, no. 6, pp. 926–934, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Miller, J. H. Price, S. P. Dobbs, R. H. McClelland, K. Kennedy, and W. G. McCluggage, “An immunohistochemical and morphological analysis of post-chemotherapy ovarian carcinoma,” Journal of Clinical Pathology, vol. 61, no. 5, pp. 652–657, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. V. T. DeVita Jr., T. S. Lawrence, S. A. Rosenberg, R. A. DePinho, and R. A. Weinberg, DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 8th edition, 2008.
  11. A. M. Goh, C. R. Coffill, and D. P. Lane, “The role of mutant p53 in human cancer,” Journal of Pathology, vol. 223, no. 2, pp. 116–126, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. S. L. Harris and A. J. Levine, “The p53 pathway: positive and negative feedback loops,” Oncogene, vol. 24, no. 17, pp. 2899–2908, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. S.-M. Ho, “Estrogen, progesterone and epithelial ovarian cancer,” Reproductive Biology and Endocrinology, vol. 1, article 73, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Lee, D. G. Rosen, C. Zhu, E. G. Silva, and J. Liu, “Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer,” Gynecologic Oncology, vol. 96, no. 3, pp. 671–677, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Korkolopoulou, A. C. Lazaris, A.-E. Konstantinidou et al., “Differential expression of bcl-2 family proteins in bladder carcinomas relationship with apoptotic rate and survival,” European Urology, vol. 41, no. 3, pp. 274–283, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Pomel, D. P. J. Barton, I. McNeish, and J. Shepherd, “A statement for extensive primary cytoreductive surgery in advanced ovarian cancer,” BJOG, vol. 115, no. 7, pp. 808–810, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Banerjee and M. Gore, “The future of targeted therapies in ovarian cancer,” Oncologist, vol. 14, no. 7, pp. 706–716, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Kumar, D. Janga, S. Berge, R. Kekkar, and J. Dominique, “Chemotherapy for advanced epithelial ovarian cancer,” Indian Journal of Medical and Paediatric Oncology, vol. 25, no. 1, pp. 21–25, 2004. View at Google Scholar
  19. G. D. Aletti, M. M. Gallenberg, W. A. Cliby, A. Jatoi, and L. C. Hartmann, “Current management strategies for ovarian cancer,” Mayo Clinic Proceedings, vol. 82, no. 6, pp. 751–770, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Lavarino, S. Pilotti, M. Oggionni et al., “p53 Gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma,” Journal of Clinical Oncology, vol. 18, no. 23, pp. 3936–3945, 2000. View at Google Scholar · View at Scopus
  21. G. Ferrandina, A. Fagotti, M. G. Salerno et al., “p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer,” British Journal of Cancer, vol. 81, no. 4, pp. 733–740, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Chu, P. Mamers, H. G. Burger, and P. J. Fuller, “Estrogen receptor isoform gene expression in ovarian stromal and epithelial tumors,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 3, pp. 1200–1205, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. L. G. Buchynska, N. P. Iurchenko, V. M. Grinkevych, I. P. Nesina, S. V. Chekhun, and V. S. Svintsitsky, “Expression of the estrogen and progesterone receptors as prognostic factor in serous ovarian cancers,” Experimental Oncology, vol. 31, no. 1, pp. 48–51, 2009. View at Google Scholar · View at Scopus
  24. J. F. Smyth, C. Gourley, G. Walker et al., “Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients,” Clinical Cancer Research, vol. 13, no. 12, pp. 3617–3622, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. J.-Y. Lee, J.-Y. Shin, H.-S. Kim et al., “Effect of combined treatment with progesterone and tamoxifen on the growth and apoptosis of human ovarian cancer cells,” Oncology Reports, vol. 27, no. 1, pp. 87–93, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. U. H. Frixen, J. Behrens, M. Sachs et al., “E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells,” Journal of Cell Biology, vol. 113, no. 1, pp. 173–185, 1991. View at Google Scholar · View at Scopus
  27. L. Larue, M. Ohsugi, J. Hirchenhain, and R. Kemler, “E-cadherin null mutant embryos fail to form a trophectoderm epithelium,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 17, pp. 8263–8267, 1994. View at Publisher · View at Google Scholar · View at Scopus
  28. F. R. Marques, G. A. Fonsechi-Carvasan, L. A. L. De Angelo Andrade, and F. Böttcher-Luiz, “Immunohistochemical patterns for α- and β-catenin, E- and N-cadherin expression in ovarian epithelial tumors,” Gynecologic Oncology, vol. 94, no. 1, pp. 16–24, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Yamauchi, V. Stearns, and D. F. Hayes, “When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer,” Journal of Clinical Oncology, vol. 19, no. 8, pp. 2334–2356, 2001. View at Google Scholar · View at Scopus
  30. G. Ferrandina, F. O. Ranelletti, L. Lauriola et al., “Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer,” Gynecologic Oncology, vol. 85, no. 2, pp. 305–310, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. E. V. S. Høgdall, L. Christensen, S. K. Kjaer et al., “Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish “MALOVA” ovarian cancer study,” Cancer, vol. 98, no. 1, pp. 66–73, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. M. A. Bookman, K. M. Darcy, D. Clarke-Pearson, R. A. Boothby, and I. R. Horowitz, “Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group,” Journal of Clinical Oncology, vol. 21, no. 2, pp. 283–290, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Camilleri-Broët, A. C. Hardy-Bessard, A. Le Tourneau et al., “HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group,” Annals of Oncology, vol. 15, no. 1, pp. 104–112, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. N. G. Cloven, A. Kyshtoobayeva, R. A. Burger, I.-R. Yu, and J. P. Fruehauf, “In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer,” Gynecologic Oncology, vol. 92, no. 1, pp. 160–166, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. T.-L. Erkinheimo, H. Lassus, P. Finne et al., “Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma,” Clinical Cancer Research, vol. 10, no. 2, pp. 538–545, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. F. D. Cirisano and B. Y. Karlan, “The role of the HER-2/neu oncogene in gynecologic cancers,” Journal of the Society for Gynecologic Investigation, vol. 3, no. 3, pp. 99–105, 1996. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Yamauchi, V. Stearns, and D. F. Hayes, “When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer,” Journal of Clinical Oncology, vol. 19, no. 8, pp. 2334–2356, 2001. View at Google Scholar · View at Scopus
  38. C. M. Lohmann, A. A. League, W. S. Clark, D. Lawson, P. B. DeRose, and C. Cohen, “Bcl-2: bax and bcl-2: Bcl-x ratios by image cytometric quantitation of immunohistochemical expression in ovarian carcinoma: correlation with prognosis,” Cytometry, vol. 42, no. 1, pp. 61–66, 2000. View at Google Scholar
  39. M. Baekelandt, G. B. Kristensen, J. M. Nesland, C. G. Tropé, and R. Holm, “Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer,” Journal of Clinical Oncology, vol. 17, no. 7, pp. 2061–2068, 1999. View at Google Scholar · View at Scopus
  40. J. Gerdes, U. Schwab, H. Lemke, and H. Stein, “Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation,” International Journal of Cancer, vol. 31, no. 1, pp. 13–20, 1983. View at Google Scholar · View at Scopus
  41. J. Gerdes, H. Lemke, H. Baisch, H. H. Wacker, U. Schwab, and H. Stein, “Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67,” Journal of Immunology, vol. 133, no. 4, pp. 1710–1715, 1984. View at Google Scholar · View at Scopus
  42. W. H. Gotlieb, I. Goldberg, B. Weisz et al., “Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer,” Gynecologic Oncology, vol. 82, no. 1, pp. 99–104, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. R. E. Bristow and D. S. Chi, “Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis,” Gynecologic Oncology, vol. 103, no. 3, pp. 1070–1076, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. I. Vergote, C. G. Tropé, F. Amant et al., “Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer,” The New England Journal of Medicine, vol. 363, no. 10, pp. 943–953, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. I. Vergote, I. De Wever, W. Tjalma, M. van Gramberen, J. Decloedt, and P. Van Dam, “Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients,” Gynecologic Oncology, vol. 71, no. 3, pp. 431–436, 1998. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Ansquer, E. Leblanc, K. Clough, P. Morice, J. Dauplat, and P. Mathevet, “Neoadjuvant chemotherapy for unresectable ovarian carcinoma,” Cancer, vol. 91, no. 12, pp. 2329–2334, 2001. View at Google Scholar
  47. J. Morrison, A. Swanton, S. Collins, and S. Kehoe, “Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD005343, 2007. View at Google Scholar · View at Scopus
  48. S. Kang and B.-H. Nam, “Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies,” Annals of Surgical Oncology, vol. 16, no. 8, pp. 2315–2320, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. G. G. Garzetti, A. Ciavattini, G. Goteri et al., “Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance,” Gynecologic Oncology, vol. 56, no. 2, pp. 169–174, 1995. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Kaern, M. Aghmesheh, J. M. Nesland et al., “Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?” International Journal of Gynecological Cancer, vol. 15, no. 6, pp. 1014–1022, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. A. K. Sood, J. I. Sorosky, M. Dolan, B. Anderson, and R. E. Buller, “Distant metastases in ovarian cancer: association with p53 mutations,” Clinical Cancer Research, vol. 5, no. 9, pp. 2485–2490, 1999. View at Google Scholar · View at Scopus
  52. S. Fallows, J. Price, R. J. Atkinson, P. G. Johnston, I. Hickey, and S. E. Russell, “P53 mutation does not affect prognosis in ovarian epithelial malignancies,” Journal of Pathology, vol. 194, no. 1, pp. 68–75, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Q. Bernardini, T. Baba, P. S. Lee et al., “Expression signatures of TP53 mutations in serous ovarian cancers,” BMC Cancer, vol. 10, article 237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. F. Bartel, J. Jung, A. Böhnke et al., “Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival,” Clinical Cancer Research, vol. 14, no. 1, pp. 89–96, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. E. Y. Cho, Y. Choi, S. W. Chae, J. H. Sohn, and G. H. Ahn, “Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms,” Pathology International, vol. 56, no. 2, pp. 62–70, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Dian, A. Brüning, and I. Mylonas, “E-cadherin as a prognostic marker in human serous carcinomas of the ovary: an immunohistochemical analysis,” Archives of Gynecology and Obstetrics, vol. 284, no. 2, pp. 437–443, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Yamamoto, H. Tsuda, T. Kita et al., “Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma,” Virchows Archiv, vol. 451, no. 1, pp. 27–35, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. R. A. M. Sagarra, L. A. L. A. Andrade, E. Z. Martinez, G. A. Pinto, K. J. Syrjänen, and S. F. M. Derchain, “P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer,” International Journal of Gynecological Cancer, vol. 12, no. 6, pp. 720–727, 2002. View at Publisher · View at Google Scholar · View at Scopus
  59. J. Kupryjańczyk, T. Szymańska, R. M̧dry et al., “Evaluation of clinical significance of TP53, BCL-2, BAX and MEKI expression in 229 ovarian carcinomas treated with platinum-based regimen,” British Journal of Cancer, vol. 88, no. 6, pp. 848–854, 2003. View at Publisher · View at Google Scholar · View at Scopus